Status:

RECRUITING

The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Lichen Planopilaris in Routine Clinical Care: a Patient Preference Trial

Lead Sponsor:

Erasmus Medical Center

Conditions:

Lichen Planopilaris

Cicatricial Alopecia

Eligibility:

All Genders

18-80 years

Brief Summary

Rationale Lichen planopilaris (LPP) is a prevalent form of cicatricial alopecia, predominantly affecting women and causing irreversible hair loss. Hydroxychloroquine (HCQ) and methotrexate (MTX) are t...

Detailed Description

Treatment of LPP remains a challenge due to limited evidence-based guidelines and a lack of randomized controlled trials, leading to the absence of standardized therapeutic protocols and outcome measu...

Eligibility Criteria

Inclusion

  • Age of 18 years and older.
  • Diagnosed with LPP.
  • Willingness to provide informed consent for participation in the study.
  • No contraindications or known allergies to HCQ or MTX.

Exclusion

  • Histopathological different diagnosis than LPP.
  • Inability to adhere to the study protocol, including medication intake, clinic visits, and questionnaire completion.
  • Patients who are ineligible for the HCQ arm (due to contraindications), are automatically included in the MTX arm.
  • Contraindications HCQ:
  • retinopathy and/or maculopathy
  • myasthenia gravis
  • body weight less than 35 kg
  • Patients who are ineligible for the MTX arm (due to contraindications), are automatically included in the HCQ arm.
  • \- Contraindications MTX:
  • Conception (both male and female) and lactation
  • Severe kidney or liver dysfunction (fibrosis, cirrhosis) or alcohol abuse
  • Bone marrow hypoplasia, immunodeficiency
  • Anemia, leukopenia, or thrombocytopenia
  • Poor nutritional status (low albumin)
  • Hypersensitivity or allergy to MTX
  • Lung toxicity due to MTX or significant reduction in lung function.

Key Trial Info

Start Date :

July 1 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

July 1 2026

Estimated Enrollment :

56 Patients enrolled

Trial Details

Trial ID

NCT06512753

Start Date

July 1 2024

End Date

July 1 2026

Last Update

July 22 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Erasmus MC

Rotterdam, South Holland, Netherlands, 3015GD